Valuation: Tempus AI, Inc.

Capitalization 7.7B 6.56B 6.07B 5.71B 10.64B 716B 10.86B 71.18B 27.85B 344B 28.88B 28.27B 1,225B P/E ratio 2026 *
-26.9x
P/E ratio 2027 * -42.1x
Enterprise value 8.32B 7.09B 6.56B 6.18B 11.5B 774B 11.74B 76.94B 30.11B 372B 31.22B 30.56B 1,324B EV / Sales 2026 *
5.23x
EV / Sales 2027 * 4.23x
Free-Float
39.62%
Yield 2026 *
-
Yield 2027 * -
1 day-2.76%
1 week-9.39%
Current month-5.04%
1 month-18.49%
3 months-35.20%
6 months-55.45%
Current year-27.28%
1 week 42.41
Extreme 42.41
50.81
1 month 41.73
Extreme 41.73
52.67
Current year 41.73
Extreme 41.73
76.33
1 year 39.01
Extreme 39.01
104.32
3 years 22.89
Extreme 22.89
104.32
5 years 22.89
Extreme 22.89
104.32
10 years 22.89
Extreme 22.89
104.32
Manager TitleAgeSince
Chief Executive Officer 56 01/08/2015
Director of Finance/CFO 40 01/08/2017
Chief Tech/Sci/R&D Officer 49 25/10/2022
Director TitleAgeSince
Chairman 56 01/08/2015
Director/Board Member 54 29/10/2019
Director/Board Member 74 01/09/2017
Change 5d. change 1-year change 3-years change Capi.($)
-2.76%-9.39%+1.95% - 7.7B
+1.74%+0.55%-1.64%-9.59% 45.62B
-1.20%-0.36%+34.42%+22.90% 34.34B
-0.89%+2.25%+28.92%+27.68% 29.46B
-0.97%-3.42%+14.97%-16.20% 28.09B
+0.22%-2.71%+169.96%+361.83% 19.11B
-1.01%+4.38%+58.47%+198.43% 14.78B
+2.31%-6.43%+2,918.75%+3,811.51% 14.25B
-1.59%-0.97%+65.77%+157.65% 14.09B
+0.25%-4.10%+35.07%+2.59% 13.25B
Average -0.39%-2.05%+332.66%+506.31% 22.07B
Weighted average by Cap. -0.15%-1.10%+224.27%+315.17%

Financials

2026 *2027 *
Net sales 1.59B 1.36B 1.26B 1.18B 2.2B 148B 2.25B 14.72B 5.76B 71.1B 5.97B 5.85B 253B 1.94B 1.66B 1.53B 1.44B 2.69B 181B 2.74B 17.98B 7.04B 86.84B 7.3B 7.14B 309B
Net income -293M -249M -231M -217M -405M -27.21B -413M -2.71B -1.06B -13.07B -1.1B -1.07B -46.56B -184M -157M -145M -137M -255M -17.15B -260M -1.71B -667M -8.24B -692M -677M -29.34B
Net Debt 623M 531M 491M 463M 862M 57.95B 879M 5.76B 2.25B 27.83B 2.34B 2.29B 99.15B 534M 455M 421M 396M 738M 49.65B 753M 4.94B 1.93B 23.84B 2B 1.96B 84.95B
Logo Tempus AI, Inc.
Tempus AI, Inc. is a technology company. The Company provides next generation diagnostics across multiple disease areas, with technology capabilities, harnessing the data and analytics to help personalize medicine. The Company’s product lines include genomics, data, and artificial intelligence applications (AI). Its genomics product line leverages its laboratories to provide next generation sequencing, diagnostics, polymerase chain reaction (PCR), profiling, molecular genotyping, and other anatomic and molecular pathology testing. The Company's AI applications are focused on developing and providing diagnostics that are algorithmic in nature, implementing new software as a medical device, and building and deploying clinical decision support tools. Its primary product of AI applications is Next, an AI platform that leverages machine learning to apply an intelligent layer onto routinely generated data to proactively identify and minimize care gaps for oncology and cardiology patients.
Employees
3,800
Date Price Change Volume
10/04/26 42.94 $ -2.76% 6,838,160
09/04/26 44.16 $ -7.03% 5,786,131
08/04/26 47.50 $ +1.46% 4,442,000
07/04/26 46.82 $ -1.03% 3,033,182
06/04/26 47.30 $ -0.19% 2,793,564
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
42.94USD
Average target price
75.43USD
Spread / Average Target
+75.66%

Quarterly revenue - Rate of surprise